The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
AML
AML outcome
ASXL1
Additional mutations
FLT3
IDH
NPM1
RUNX1
TP53
WT1
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
12
2018
accepted:
28
03
2019
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study was to investigate if somatic mutations could represent an additional prognostic value in respect of MRD alone. At baseline, 98 patients were tested for Overall, 60.2% of our patients resulted mutated: 24.5% carried mutations of We demonstrated that additional somatic mutations are able to impair outcome of the already MRD-negative subjects. About MRD, we suggest a prognostic role also for the
Sections du résumé
BACKGROUND
BACKGROUND
In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study was to investigate if somatic mutations could represent an additional prognostic value in respect of MRD alone.
METHOD
METHODS
At baseline, 98 patients were tested for
RESULTS
RESULTS
Overall, 60.2% of our patients resulted mutated: 24.5% carried mutations of
CONCLUSIONS
CONCLUSIONS
We demonstrated that additional somatic mutations are able to impair outcome of the already MRD-negative subjects. About MRD, we suggest a prognostic role also for the
Identifiants
pubmed: 30992690
doi: 10.1186/s12935-019-0807-0
pii: 807
pmc: PMC6449954
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Blood. 2001 Apr 15;97(8):2434-9
pubmed: 11290608
EMBO J. 2001 Apr 17;20(8):1897-909
pubmed: 11296223
Blood. 2001 Sep 15;98(6):1752-9
pubmed: 11535508
Br J Haematol. 2002 Feb;116(2):409-20
pubmed: 11841446
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858
Best Pract Res Clin Haematol. 2003 Dec;16(4):599-612
pubmed: 14592645
Blood Rev. 2004 Jun;18(2):115-36
pubmed: 15010150
N Engl J Med. 2005 Jan 20;352(3):254-66
pubmed: 15659725
Blood. 2005 Dec 1;106(12):3733-9
pubmed: 16076867
Leukemia. 2006 Jul;20(7):1217-20
pubmed: 16642044
Br J Haematol. 2006 Oct;135(2):165-73
pubmed: 16939487
Blood. 2007 Feb 1;109(3):874-85
pubmed: 17008539
Blood. 2008 Mar 1;111(5):2776-84
pubmed: 17957027
N Engl J Med. 2008 May 1;358(18):1909-18
pubmed: 18450602
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Blood. 2009 Oct 1;114(14):3024-32
pubmed: 19429869
J Clin Oncol. 2009 Nov 1;27(31):5195-201
pubmed: 19752335
Blood. 2009 Dec 17;114(26):5352-61
pubmed: 19808697
Blood. 2009 Nov 12;114(20):4601-2; author reply 4602-3
pubmed: 19965707
Br J Haematol. 2010 May;149(3):451-4
pubmed: 20085581
Blood. 2010 Jun 24;115(25):5222-31
pubmed: 20368469
Blood. 2011 Jan 27;117(4):1109-20
pubmed: 21030560
Biochem Res Int. 2011;2011:195209
pubmed: 21152184
J Clin Oncol. 2011 Jul 1;29(19):2709-16
pubmed: 21555683
Arch Pathol Lab Med. 2011 Nov;135(11):1504-9
pubmed: 22032582
Haematologica. 2012 Aug;97(8):1242-5
pubmed: 22532519
Cancer. 2012 Nov 15;118(22):5550-9
pubmed: 22569880
Blood. 2013 Jul 4;122(1):100-8
pubmed: 23704090
Leukemia. 2013 Sep;27(9):1891-901
pubmed: 23783394
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
J Clin Oncol. 2013 Nov 1;31(31):3889-97
pubmed: 24062400
PLoS One. 2014 Mar 07;9(3):e89560
pubmed: 24608088
Biochemistry. 1989 Nov 28;28(24):9495-501
pubmed: 2482073
Mod Pathol. 2015 May;28(5):706-14
pubmed: 25412851
Haematologica. 2015 Dec;100(12):e487-90
pubmed: 26294738
Haematologica. 2016 Jun;101(6):672-9
pubmed: 27252512
Blood Cancer J. 2016 Jul 08;6(7):e442
pubmed: 27391574
N Engl J Med. 2016 Aug 11;375(6):e9
pubmed: 27509124
Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):1-7
pubmed: 27613372
Leukemia. 2017 Feb;31(2):272-281
pubmed: 27721426
Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052
pubmed: 27872732
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):null
pubmed: 28003281
Curr Med Res Opin. 2018 May;34(5):757-763
pubmed: 28027687
Indian J Hematol Blood Transfus. 2017 Mar;33(1):49-55
pubmed: 28194056
Cell. 2017 Feb 23;168(5):801-816.e13
pubmed: 28215704
Biomed Res Int. 2017;2017:5473197
pubmed: 28286768
J Mol Diagn. 2017 Jul;19(4):537-548
pubmed: 28525762
Int J Hematol. 2017 Oct;106(4):552-561
pubmed: 28616699
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Curr Hematol Malig Rep. 2017 Dec;12(6):547-556
pubmed: 29027628
Cell. 1989 Feb 10;56(3):379-90
pubmed: 2914325
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221
Expert Rev Hematol. 2018 Apr;11(4):307-313
pubmed: 29495904
Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):636-647
pubmed: 30006258
Int J Mol Sci. 2018 Nov 06;19(11):null
pubmed: 30404199
Blood Adv. 2018 Nov 27;2(22):3118-3125
pubmed: 30455361
Oncotarget. 2018 Nov 27;9(93):36613-36624
pubmed: 30564301
Leukemia. 1994 Dec;8(12):2138-43
pubmed: 7808002
Leukemia. 1997 May;11(5):639-43
pubmed: 9180285